Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 7/20 | 0.55 |
| ▸ | HTR6 | P50406 | 7/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | SCARB1 | Q8WTV0 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2025854 | 0.99 | HTR6 (0.54) | HRH1HTR6EGFRIGF1RFLT4 | |
| Hydrochloric Acid SCHEMBL2024394 | 0.99 | HTR6 (0.54) | HRH1HTR6EGFRIGF1RFLT4 | |
| SCHEMBL3150253 | 0.91 | HTR6 (0.57) | HRH1HTR6EGFRIGF1RFLT4 | |
| SCHEMBL19015842 | 0.88 | HRH1 (0.55) | HRH1HTR6SCARB1CNR2AR | |
| SCHEMBL16493815 | 0.88 | HRH1 (0.43) | HRH1HTR6EGFRIGF1RFLT4 | |
| Hydrochloric Acid SCHEMBL17592674 | 0.87 | HTR6 (0.54) | HRH1HTR6EGFRIGF1RFLT4 | |
| SCHEMBL14218080 | 0.85 | EGFR (0.42) | HRH1HTR6EGFRIGF1RFLT4 | |
| SCHEMBL2019197 | 0.84 | HRH1 (0.40) | HRH1HTR6SCARB1 | |
| SCHEMBL12579014 | 0.84 | HRH1 (0.40) | HRH1HTR6SCARB1 | |
| SCHEMBL2024874 | 0.82 | HRH1 (0.48) | HRH1HTR6SCARB1CNR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148694-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2024-05-09 | — | — | US | disclosed |
| US-20200390744-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390744-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2020-12-17 | — | — | US | disclosed |
| US-10799478-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799478-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-10-13 | — | — | US | disclosed |
| US-10758515-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758515-B2 | Treatment of androgen deprivation therapy associated symptoms | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3191094-B1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | LILLY CO ELI (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3191094-B1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | LILLY CO ELI (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190111039-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2019-04-18 | — | — | US | disclosed |
| US-20170172992-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY | 2017-06-22 | — | — | US | disclosed |
| WO-2016040234-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | ELI LILLY AND COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2094658-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2094658-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148694-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HRH1 2142/4885HTR6 634/4885EGFR 720/4885 |
| US-20190111039-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HRH1 2142/4885HTR6 634/4885EGFR 720/4885 |
| US-20200390744-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, SHBG | HRH1 2142/4885HTR6 634/4885EGFR 720/4885 |
| US-20170172992-A1 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | NR5A1, CYP17A1, AR | HRH1 2079/4885HTR6 895/4885EGFR 400/4885 |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | HRH1 1313/4885HTR6 251/4885EGFR 1267/4885 |
| US-10758515-B2 | Treatment of androgen deprivation therapy associated symptoms | NR5A1, CYP17A1, SHBG | HRH1 1830/4885HTR6 759/4885EGFR 679/4885 |
| US-10799478-B2 | Treatment of androgen deprivation therapy associated symptoms | NR5A1, CYP17A1, SHBG | HRH1 2142/4885HTR6 634/4885EGFR 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.